A new imaging technique could mean patients with aggressive brain tumours benefit from cutting edge immunotherapy treatments, ...

A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

Dr Jessica May Hislop joined The Institute of Cancer Research as a Bioinformatician in the Houlston Lab in the Genetics and Epidemiology division. Together with her colleagues, she is working towards ...

Help women with ovarian and breast cancer live longer and better lives by supporting the Institute of Cancer Research. Donate ...

Applications are now open for our 2024/2025 PhD studentships. Below you will find a link to further information about our application process, our application portal and mailing list, should you wish ...

Cancer Research UK (CRUK) has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a ...

Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study ...

Image: Cyberknife People with intermediate risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as ...

Image: Blood samples in tubes. Doctors could predict whether a man’s prostate cancer will be aggressive at the point of diagnosis – giving him the best targeted treatment quickly before it spreads – ...

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer, paving the way for better risk assessment and more ...

A pioneering research study which will allow brain cancer patients to access drugs that are precisely targeted to their disease and swap to different treatments if needed, has launched in the UK. The ...

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy. The ...